Current progress in enteropathogenic and enterohemorrhagic Escherichia coli vaccines

Expert Review of Vaccines

Volumn 1, Issue 4, 2002, Pages 483-493

  Horne, Cathy ^a   Vallance, Bruce A ^a   Deng, Wanyin ^a   Finlay, B Brett ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Diarrhea; EHEC; EPEC; HUS; Mucosal vaccines; Virulence factors

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; ESCHERICHIA COLI VACCINE; INTIMIN; RECOMBINANT PROTEIN; TOXOID;

DEVELOPING COUNTRY; DIARRHEA; DRUG RESEARCH; DRUG TARGETING; EPIDEMIC; ESCHERICHIA COLI; HEALTH HAZARD; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HOST; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; ESCHERICHIA COLI VACCINES; HUMANS; LIPOPOLYSACCHARIDES;

EID: 0037653690     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.1.4.483     Document Type: Review

References (67)

1. Vallance BA, Finlay BB. Exploitation of host cells by enteropathogenic Eschrichia coli. Proc. Natl Acad. Sci. USA 97(16), 8799-8806 (2000).
2. Frankel G, Phillips AD, Rosenshine I et al. Enteropathogenic and enterohaemorrhagic Escherichia coli: more subversive elements. Mol. Microbiol. 30(5), 911-921 (1998).
3. Nataro J, Kaper J. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 11142-11201 (1998).
4. DeVinney R, Gauthier A, Abe A et al. Enteropathogenic Escherichia coli: a pathogen that inserts its own receptor into host cells. Cellular Mol. Life Sci. 55(6-7), 961-976 (1999).
5. Viljanen MK, Peltola T, Junnila SY et al. Outbreak of diarrhoea due to Escherichia coli O111:B4 in schoolchildren and adults: association of Vi antigen-like reactivity. Lancet 336(8719), 831-834 (1990).
6. Law D. Virulence factors of Escherichia coli O157 and other Shiga toxin-producing E. coli. J. Appl. Microbiol. 88(5), 729-745 (2000).
7. Armstrong GL, Hollingsworth J, Morris JG Jr. Emerging foodborne pathogens: Escherichia coli O157:H7 as a model of entry of a new pathogen into the food supply of the developed world. Epidemiologic Rev. 18(1), 29-51 (1996).
8. Donnenberg M. Enteropathogenic Escherichia coli. In: Infections of the gastrointestinal tract. Blaser M et al, (Eds) Raven Press, New York, NY, USA (1995).
9. Walterspiel JN, Ashkenazi S, Morrow AL et al. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection 20(1), 25-29 (1992).
10. Blank TE, Zhong H, Bell AL et al. Molecular variation among Type IV pilin (bfpA) genes from diverse enteropathogenic Escherichia coli strains. Infect. Immun. 68(12), 7028-7038 (2000).
11. McDaniel TK, Kaper JB. A cloned pathogenicity island from enteropathogenic Escherichia coli confers the attaching and effacing phenotype on E. coli K-12. Mol. Microbiol. 23(2), 399-407 (1997).
12. Jarvis KG, Giron JA, Jerse AE et al. Enteropathogenic Escherichia coli contains a putative Type III secretion system necessary for the export of proteins involved in attaching and effacing lesion formation. Proc. Natl Acad. Sci. USA 92(17), 7996-8000 (1995). First demonstration that EPEC possesses a Type III secretion system.
13. Jarvis KG, Kaper JB. Secretion of extracellular proteins by enterohemorrhagic Escherichia coli via a putative Type III secretion system. Infect. Immun. 64(11), 4826-4829 (1996).
14. Elliott SJ, Wainwright LA, McDaniel TK et al. The complete sequence of the locus of enterocyte effacement (LEE) from enteropathogenic Escherichia coli E2348/69. Mol. Microbiol. 28(1), 1-4 (1998).
15. Knutton S, Rosenshine I, Pallen MJ et al. A novel EspA-associated surface organelle of enteropathogenic Escherichia coli involved in protein translocation into epithelial cells. EMBO 17(8), 2166-2176 (1998).
16. Ebel F, Podzadel T, Rohde M et al. Initial binding of Shiga toxin-producing Escherichia coli to host cells and subsequent induction of actin rearrangements depend on filamentous EspA-containing surface appendages. Mol. Microbiol. 30(1), 147-161 (1998).
17. Daniell SJ, Takahashi N, Wilson R et al. The filamentous Type III secretion translocon of enteropathogenic Escherichia coli. Cell Microbiol. 3(12I), 865-871 (2001).
18. Sekiya K, Ohishi M, Ogino T et al. Supermolecular structure of the enteropathogenic Escherichia coli Type III secretion system and its direct interaction with the EspA-sheath-like structure. Proc. Natl Acad. Sci. USA 98(20), 11638-11643 (2001).
19. Wilson RK, Shaw RK, Daniell S et al. Role of EscF, a putative needle complex protein, in the Type III protein translocation system of enteropathogenic Escherichia coli. Cell Microbiol. 3(11), 753-762 (2001).
20. Ide T, Laarmann S, Greune L et al. Characterization of translocation pores inserted into plasma membranes by Type III-secreted Esp proteins of enteropathogenic Escherichia coli. Cell Microbiol. 3(10), 669-679 (2001).
21. Shaw RK, Daniell S, Ebel F et al. EspA filament-mediated protein translocation into red blood cells. Cell Microbiol. 3(4), 213-222 (2001).
22. Wachter C, Beinke C, Mattes M et al. Insertion of EspD into epithelial target cell membranes by infecting enteropathogenic Escherichia coli. Mol. Microbiol. 31(6), 1695-1707 (1999).
23. Warawa J, Finlay BB, Kenny B. Type III secretion-dependent hemolytic activity of enteropathogenic Escherichia coli. Infect Immun. 67(10), 5538-5540 (1999).
24. DeVinney R, Stein M, Reinscheid D et al. Enterohemorrhagic Escherichia coli O157:H7 produces Tir, which is translocated to the host cell membrane but is not tyrosine phosphorylated. Infect. Immun. 67(5), 2389-2398 (1999).
25. Kenny B, DeVinney R, Stein M et al. Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into mammalian cells. Cell 91(4I), 511-520 (1997). Seminal finding that EPEC translocates its own receptor Tir into host cells.
26. DeVinney R, Puente JL, Gauthier A et al. Enterohaemorrhagic and enteropathogenic Escherichia coli use a different Tir-based mechanism for pedestal formation. Mol. Microbiol. 41(6), 1445-1458 (2001).
27. Goosney DL, DeVinney F, Finlay BB. Recruitment of cytoskeletal and signaling proteins to enteropathogenic and enterohemorrhagic Escherichia coli pedestals. Infect. Immun. 69(5), 3315-3322 (2001).
28. Luo Y, Frey EA, Pfuetzner RA et al. Crystal structure of enteropathogenic Escherichia coli intimin-receptor complex. Nature 405(6790), 1073-1077 (2000). First demonstration of crystal structure of the intimin-Tir complex.
29. Ray PE, Liu XH. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr. Nephrol. 16(10), 823-839 (2001).
30. An H, Fairbrother JM, Desautels C et al. Presence of the LEE (locus of enterocyte effacement) in pig attaching and effacing Escherichia coli and characterization of eae, espA, espB and espD genes of PEPEC (pig EPEC) strain 1390. Microbial Pathogenesis 28(5), 291-300 (2000).
31. Dean-Nystrom EA, Bosworth BT, Cray WC Jr. et al. Pathogenicity of Escherichia coli O157:H7 in the intestines of neonatal calves. Infect. Immun. 65(5), 1842-8 (1997).
32. Tzipori S, Gunzer F, Donnenberg MS et al. The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic Escherichia coli infection. Infect. Immun. 63(9), 3621-3627 (1995).
33. Dean-Nystrom EA, Pohlenz JF, Moon HW et al. Escherichia coli O157:H7 causes more severe systemic disease in suckling piglets than in colostrum-deprived neonatal piglets. Infect. Immun. 68(4), 2356-2358 (2000).
34. Karpman D, Connell H, Svensson M et al. The role of lipopolysaccharide and Shiga like toxin in a mouse model of Escherichia coli O157:H7 infection. J. Infect. Dis. 175(3), 611-620 (1997).
35. Taguchi H, Takahashi M, Yamaguchi H et al. Experimental infection of germ-free mice with hyper-toxigenic enterohaemorrhagic Escherichia coli O157:H7, strain 6. J. Med. Microbiol. 51(4), 336-343 (2002).
36. Conlan JW, Perry MB. Susceptibility of three strains of conventional adult mice to intestinal colonization by an isolate of Escherichia coli O157:H7. Can. J. Microbiol. 44(8), 800-805 (1998).
37. Woods JB, Schmitt CK, Darnell SC et al. Ferrets as a model system for renal disease secondary to intestinal infection with Escherichia coli O157:H7 and other Shiga toxin-producing E. coli. J. Infect. Dis. 185(4), 550-554 (2002).
38. Cantey JR, Blake RK. Diarrhea due to Escherichia coli in the rabbit: a novel mechanism. J. Infect. Dis. 135(3), 454-462 (1977).
39. Agin TS, Cantey JR, Boedeker EC et al. Characterization of the eaeA gene from rabbit enteropathogenic Escherichia coli strain RDEC-1 and comparison to other eaeA genes from bacteria that cause attaching-effacing lesions. FEMS Microbiol. Lett. 144(2-3), 249-58 (1996).
40. Luperchio S. Molecular pathogenesis of Citrobacter rodentium and transmissible murine colonic hyperplasia. Microbes Infection 3333-3340 (2001).
41. Dean-Nystrom EA, Bosworth BT, Moon HW. Pathogenesis of O157:H7 Escherichia coli infection in neonatal calves. Adv. Exp. Med. Biol. 41247-41251 (1997).
42. Dean-Nystrom EA, Bosworth BT, Moon HW et al. Echerichia coli O157:H7 requires intimin for enteropathogenicity in calves. Infect. Immun. 66(9), 4556-4563 (1998).
43. Bitzan M, Moebius E, Ludwig K et al. High incidence of serum antibodies to Escherichia coili O157 lipopolysaccharide in children with hemolytic-uremic syndrome. J. Pediatr. 119(31), 380-385 (1991).
44. Li Y, Frey E, Mackenzie AM et al. Human response to Escherichia coli O157:H7 infection: antibodies to secreted virulence factors. Infect. Immun. 68(9), 5090-5095 (2000). First demonstration that EHEC-secreted virulence factors are recognized by the host antibody.
45. Manjarrez-Hernandez HA, Gavilanes-Parra S, Chavez-Berrocal E et al. Antigen detection in enteropathogenic Escherichia coli using secretory immunoglobulin A antibodies isolated from human breast milk. Infect. Immun. 68(9), 5030-5036 (2000).
46. Loureiro I, Frankel G, Adu-Bobie J et al. Human colostrum contains IgA antibodies reactive to enteropathogenic Escherichia coli virulence-associated proteins: intimin, BfpA, EspA and EspB. J. Pediatar. Gastroenterol. Nutr. 27(2), 166-171 (1998).
47. Donnenberg MS, Tacket CO, James SP et al. Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. J. Clin. Invest. 92(3I), 1412-1417 (1993).
48. Tacket CO, Sztein MB, Losonsky G et al. Role of EspB in experimental human enteropathogenic Escherichia coli infection. Infect. Immun. 68(6), 3689-3695 (2000). Well-performed human volunteer study with EPEC.
49. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin. Microbiol. Rev. 11(3), 450-479 (1998).
50. Higgins LM, Frankel G, Douce G et al. Citrobacter rodendum infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease. Infect. Immun. 67(6), 3031-3039 (1999). First thorough examination of the host immune response to infection by an A/E pathogen.
51. Vallance BA, Deng W, Knodler LA et al. Mice lacking T and B-lymphocytes develop transient colitis and crypt hyperplasia yet suffer impaired bacterial clearance during Citrobacter rodentium infection. Infect. Immun. 70(4), 2070-2081 (2002).
52. Proulx F, Litalien C, Turgeon JP et al. Circulating levels of transforming growth factor-beta1 and lymphokines among children with hemolytic uremic syndrome. Am. J. Kidney Diseases 35(1I), 29-34 (2000).
53. Ghaem-Maghami M, Simmons CP, Daniell S et al. Intimin-specific immune responses prevent bacterial colonization by the attaching-effacing pathogen Citrobacter rodentium. Infect. Immun. 69(9), 5597-5605 (2001). Demonstration of the usefulness of C. rodentium model in testing of vaccines and the role of intimin.
54. Dean-Nystrom E, Gansheroff L, Mills M et al. Vaccination of pregnant dams with intimin o157 Protects Suckling Piglets from Escherichia coli O157:H7 infection. Infect. Immun. 70(5), 2414 (2002).
55. Stewart C, Wachtel M, Mabon S et al. Expression of enterohemorrhagic Escherichia coli intimin in transgenic plants: an edible antiEHEC O157:H7 vaccine candidate. In: International Symposium and Workshop on Shiga Toxin-producing Escherichia coli: Lois Joy Galler Foundation for Hemolytic Uremic Syndrome, Inc. (1997).
56. Schriefer A, Maltez JR, Silvan et al. Expression of a pilin subunit BfpA of the bundle-forming pilus of enteropathogenic Escherichia coli in an aroA live salmonella vaccine strain. Vaccine 17(7-8), 770-778 (1999).
57. Quintana Flores V, Campos de Souza Fernandes R, Sousa de Macedo Z et al. Expression and purification of the recombinant enteropathogenic Escherichia coli vaccine candidates BfpA and EspB. Protein Expression Purification 2516-22 (2002).
58. Vieira de Silva J, Garcia A, Quintana Flores V et al. Phytosecretion of enteropathogenic Escherichia coli pilin subunit a in transgenic tobacco and its suitability for early life vaccinology. Vaccine 202091-202101 (2002).
59. Konadu EY, Parke JC Jr, Tran HT et al. Investigational vaccine for Escherichia coli O157: Phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults. J. Infect. Dis. 177(2), 383-387 (1998).
60. Konadu E, Donohue-Rolfe A, Calderwood SB et al. Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice. Infect. Immun. 67(11), 6191-6193 (1999).
61. Fukuda T, Kimiya T, Takahashi M et al. Induction of protection against oral infection with cytotoxin-producing Escherichia coli O157:H7 in mice by shiga-like toxin-liposome conjugate. Intl Arch. Allergy Immunol. 116(4), 313-317 (1998).
62. Butterton JR, Ryan ET, Acheson DW et al. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains Infect. Immun. 65(6), 2127-2135 (1997).
63. Marcato P, Mulvey G, Read RJ et al. Immunoprophylactic potential of cloned shiga toxin 2 B subunit. J Infect Dis 183(3), 435-443 (2001).
64. Acheson DW, Levine MM, Kaper JB et al. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infect. Immun. 64(1), 355-357 (1996).
65. Bielaszewska M, Clarke I, Karmali MA et al. Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits. Infect. Immun. 65(7), 2509-2516 (1997).
66. Nakao H, Kiyokawa N, Fujimoto J et al. Monoclonal antibody to Shiga toxin 2 which blocks receptor binding and neutralizes cytotoxicity. Infect. Immun. 67(11), 5717-5722 (1999).
67. Mukherjee J, Chios K, Fishwild D et al. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect. Immun. 70(2), 612-619 (2002).